Merck's Keytruda (pembrolizumab) has hit the mark in the late-stage NRG-GY018 trial, with a combination of the drug plus chemotherapy improving progression-free survival (PFS) versus chemo alone ...

The NCI will lead the trial of the firm's Versamune MUC1 immunotherapy and its antibody-drug conjugate PDS01ADC.

Summit Therapeutics (NASDAQ: SMMT) has been one of the hottest stocks to own over the past 12 months, with its valuation ...

The combination demonstrated non-inferiority to comparator antiretroviral therapies, meeting the primary efficacy success ...

DelveInsight's "VERZENIO Market Size, Forecast, and Market Insight Report" highlights the details around VERZENIO, which is a targeted treatment known as ...

The Trump administration is withdrawing the CDC nominee Dave Weldon as his anti-vaccine views came to the fore before a ...

Moderna stock is under pressure, again, as Robert F. Kennedy Jr. reportedly mulls pulling the company's federal funding to ...

Kioxia Corporation has been named a Clarivate Top 100 Global Innovators 2025, an award given to the most innovative global companies by Clarivate Plc. This is the fourth time Kioxia has received this ...

The top 10 projected best-selling medications in 2026, including GLP-1 drugs and AbbVie's Skyrizi, have expected global sales reaching up to $31 billiion.